Trovagene Receives Approximately $3.0 Million From Exercise of Warrants

SAN DIEGO, March 13, 2019

"We are pleased with recent activities as more investors are becoming aware of our multi-faceted clinical development program of Onvansertib, a first-in-class, 3^rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor," said Thomas Adams, Chief Executive Officer and Chairman of Trovagene. "Our program currently includes three open-label trials - Acute Myeloid Leukemia, metastatic Castration Resistant Prostate Cancer and metastatic Colorectal Cancer - all of which are indications where there is a significant need to bring new treatment options to patients."

About Trovagene, Inc.

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.  For more information, please visit https://www.trovageneoncology.com.

Trovagene Contact:
Vicki Kelemen
VP, Clinical Development
858-952-7652
vkelemen@trovagene.com